Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA 's risk evaluation and mitigation strategy lifecycle

2021 ◽  
Vol 30 (5) ◽  
pp. 626-635
Author(s):  
Amarilys Vega ◽  
Rongmei Zhang ◽  
Hui‐Lee Wong ◽  
Michael Wernecke ◽  
Michael Alexander ◽  
...  
Keyword(s):  
Risk Evaluation ◽  
Mitigation Strategy ◽  
Blood Transfusions

scholarly journals Clozapine and Agranulocytosis: Impact of the Risk Evaluation and Mitigation Strategy Program

2018 ◽  
Vol 21 ◽  
pp. S180
Author(s):  
EP Borrelli ◽  
EY Lee ◽  
AM Descoteaux ◽  
AR Caffrey
Keyword(s):  
Risk Evaluation ◽  
Mitigation Strategy

US Food and Drug Administrationʼs Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids

Drugs ◽  
2012 ◽  
Vol 72 (18) ◽  
pp. 2327-2332 ◽  
Author(s):  
Sebastiano Mercadante ◽  
David Craig ◽  
Antonello Giarratano
Keyword(s):  
Risk Evaluation ◽  
Extended Release ◽  
Mitigation Strategy ◽  
Long Acting

scholarly journals Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology

2014 ◽  
Vol 21 (e2) ◽  
pp. e358-e362 ◽  
Author(s):  
Demetra S Tsapepas ◽  
Jaclyn T McKeen ◽  
Spencer T Martin ◽  
Jennifer K Walker-McDermott ◽  
Alex Yang ◽  
...  
Keyword(s):  
Information Technology ◽  
Organ Transplantation ◽  
Risk Evaluation ◽  
Solid Organ Transplantation ◽  
Mitigation Strategy ◽  
Solid Organ

Inpatient pharmacy experience with an audit for a risk evaluation and mitigation strategy for riociguat

2017 ◽  
Vol 74 (21) ◽  
pp. 1762-1763 ◽  
Author(s):  
Zachary R. Smith ◽  
Charles T. Makowski ◽  
Nancy C. MacDonald
Keyword(s):  
Risk Evaluation ◽  
Mitigation Strategy
Sign in / Sign up

Export Citation Format

Share Document